Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Around 80–90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence, androgen ablation therapy directed toward a reduction in serum androgens and the inhibition of androgen receptor (AR) is generally the first therapy adopted. However, the patient’s response to androg...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cells
Glavni autori: Aurilio, Gaetano, Cimadamore, Alessia, Mazzucchelli, Roberta, Lopez-Beltran, Antonio, Verri, Elena, Scarpelli, Marina, Massari, Francesco, Cheng, Liang, Santoni, Matteo, Montironi, Rodolfo
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7763510/
https://ncbi.nlm.nih.gov/pubmed/33321757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells9122653
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items